Skip to main content
All lobbying filings

Forbes-Tate

Forbes-Tate filed a Q1 termination report for House RX on April 4, 2025.

Lobbying for House RX · Establishes on-site specialty pharmacies within physician group offices.

As filed: FORBES-TATE for HOUSE RX.

All filings by Forbes-Tate · Everything House RX has reported

 Filing · LD-2 quarterly report Q1 termination
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 4, 2025
Money reported
None
Registrations and no-activity reports carry no figure.
Client based in
California
Representation ended
Jan 1, 2025
The registrant reported terminating its work for this client.

Official filing document

 Government bodies contacted 2

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 2
Health Issues

Issues related to H.R. 5526/S. 3458 - Seniors Access to Critical Medications Act of 2023.

Medicare/Medicaid

Issues related to H.R. 5526/S. 3428 - Seniors Access to Critical Medications Act of 2023.

 Bills named in this filing 3
  • H.R. 5526
    Seniors’ Access to Critical Medications Act of 2024
  • S. 3458
    Seniors’ Access to Critical Medications Act of 2023
  • S. 3428
    SAFE Crypto Act

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem